Compare KRRO & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | RDIB |
|---|---|---|
| Founded | 2014 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.9M | 204.5M |
| IPO Year | 2019 | 1994 |
| Metric | KRRO | RDIB |
|---|---|---|
| Price | $13.29 | $9.00 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $34.80 | N/A |
| AVG Volume (30 Days) | ★ 128.3K | 11.6K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.76 |
| EPS | N/A | ★ N/A |
| Revenue | $6,392,000.00 | ★ $202,988,000.00 |
| Revenue This Year | N/A | $16.25 |
| Revenue Next Year | N/A | $4.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $8.01 |
| 52 Week High | $55.89 | $17.40 |
| Indicator | KRRO | RDIB |
|---|---|---|
| Relative Strength Index (RSI) | 60.71 | 50.77 |
| Support Level | $9.76 | $8.49 |
| Resistance Level | $14.53 | $10.50 |
| Average True Range (ATR) | 0.78 | 0.35 |
| MACD | 0.32 | 0.04 |
| Stochastic Oscillator | 83.25 | 47.37 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.